NEW YORK (GenomeWeb News) – Pathogenica today announced that it has signed a co-marketing pact with Life Technologies for sequencing-based diagnostic tests targeting hospital-acquired infections.

The exclusive deal covers Europe, the Middle East, and Africa and will combine Pathogenica's DxSeq technology with Life Tech's Ion Torrent PGM platform. The kits will be distributed for research use, the firms said, and are not for use in diagnosing hospital patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.